What You Should Know:
– SHINE Technologies, a nuclear fusion company with an expanding platform of medical isotope products, today announced it has entered into a definitive agreement to acquire the SPECT (Single-Photon Emission Computed Tomography) business from Lantheus, a leading radiopharmaceutical-focused company.
– The strategic acquisition includes the portion of Lantheus’ North Billerica, Massachusetts campus dedicated to the manufacturing of its SPECT products.
SHINE’s Expanding Isotope Production Capabilities
This acquisition complements SHINE’s significant investments in isotope production infrastructure. The company’s large-scale irradiation facility, “Chrysalis,” is poised to become the largest isotope production facility in the world. Once operational, Chrysalis will play a crucial role in the existing supply chain, ensuring a sustainable and reliable source of vital isotopes. These include Molybdenum-99 (Mo-99), the world’s most widely-used medical isotope, and Lutetium-177 (Lu-177), recognized as the most widely-used cancer-fighting isotope.
Further bolstering its production capacity, SHINE opened one of the largest facilities in the Western Hemisphere last year specifically dedicated to producing non-carrier-added lutetium-177. This facility currently has a production capacity of up to 100,000 doses of Lu-177 per year, with the potential to expand to 200,000 doses annually.
SHINE’s Broader Vision: From Medical Isotopes to Fusion Energy
Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion technology, developing innovative solutions that emphasize safety, cost-efficiency, and environmental responsibility. The company has successfully commercialized fusion applications in neutron testing markets, including neutron radiography and radiation-effects testing.
Beyond its scaling medical isotope production for diagnosing heart disease and cancer, as well as for cancer therapy, SHINE is also pioneering nuclear waste recycling to enhance the sustainability of nuclear energy. The company’s long-term vision is to transform energy production through the commercialization of fusion energy, following a commercially driven path similar to successful deep-tech industries. This acquisition of Lantheus’ SPECT business is another strategic step in SHINE’s multi-faceted approach to leveraging fusion technology for widespread benefit.
